Oramed(US:ORMP)2025-11-17 14:05Share Repurchase and Financial Management - On October 20, 2025, Oramed Pharmaceuticals Inc. repurchased 1,155,367 shares at a price of $2.23 per share, totaling $2,576,468.41[4] - The repurchase agreement reflects the company's commitment to managing its capital structure effectively[4] - The share repurchase and termination of the joint venture are part of the company's strategic adjustments in response to market conditions[4][7] Joint Venture and Strategic Decisions - The company terminated its Joint Venture Agreement with HTIT Biotech due to unmet closing conditions, effective October 23, 2025[7] - The company continues to explore opportunities for market expansion and new product development despite recent challenges[7] Financial Information and Cautionary Notes - Preliminary financial information as of September 30, 2025, was issued in a Shareholder Letter, but it is unaudited and subject to future adjustments[8] - The company cautioned that the financial information provided should not be relied upon for investment decisions, as it may materially vary from actual results[9] - The company has not completed its quarter-end financial close processes, indicating potential changes in reported results[9] - The financial information disclosed is based on management's estimates and assumptions, highlighting the preliminary nature of the data[9] Business Strategy Focus - The company remains focused on its oral drug delivery technology as a core aspect of its business strategy[6]